Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evacetrapib PK/PD and DDI with Statins in Healthy Chinese Subjects
NCT02156492Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evacetrapib in hypercholesterolemia (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under Curve (AUC 0-inf) of Evacetrapib at Day 14, Maximum Concentration (Cmax) of Evacetrapib at Day 14 and 3 more. Started Jun 2014; status: completed.
02
Drugs
evacetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02156492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156492.